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Differential Responses of Plasma 
Adropin Concentrations To Dietary 
Glucose or Fructose Consumption 
In Humans
Andrew A. Butler1, Marie-Pierre St-Onge2, Emily A. Siebert1, Valentina Medici3, 
Kimber L. Stanhope4 & Peter J. Havel4
Adropin is a peptide hormone encoded by the Energy Homeostasis Associated (ENHO) gene whose 
physiological role in humans remains incompletely defined. Here we investigated the impact 
of dietary interventions that affect systemic glucose and lipid metabolism on plasma adropin 
concentrations in humans. Consumption of glucose or fructose as 25% of daily energy requirements 
(E) differentially affected plasma adropin concentrations (P < 0.005) irrespective of duration, 
sex or age. Glucose consumption reduced plasma adropin from 3.55 ± 0.26 to 3.28 ± 0.23 ng/ml 
(N = 42). Fructose consumption increased plasma adropin from 3.63 ± 0.29 to 3.93 ± 0.34 ng/ml 
(N = 45). Consumption of high fructose corn syrup (HFCS) as 25% E had no effect (3.43 ± 0.32 versus 
3.39 ± 0.24 ng/ml, N = 26). Overall, the effect of glucose, HFCS and fructose on circulating adropin 
concentrations were similar to those observed on postprandial plasma triglyceride concentrations. 
Furthermore, increases in plasma adropin levels with fructose intake were most robust in individuals 
exhibiting hypertriglyceridemia. Individuals with low plasma adropin concentrations also exhibited 
rapid increases in plasma levels following consumption of breakfasts supplemented with lipids. 
These are the first results linking plasma adropin levels with dietary sugar intake in humans, with the 
impact of fructose consumption linked to systemic triglyceride metabolism. In addition, dietary fat 
intake may also increase circulating adropin concentrations.
Rapid effects of fasting and feeding on adropin expression in mice suggest functions related to meta-
bolic adaptation. Consistent with this hypothesis, adropin-knockout mice are insulin resistant1. Adropin 
therapy enhances glucose clearance, improves hyperinsulinemia and enhances muscle insulin action in 
diet-induced obese (DIO) mice2,3. Adropin may defend against body obesity, with adropin therapy and 
overexpression producing lean phenotypes2. Adropin also functions as a nutrient-sensing peptide hor-
mone signaling nutrient/caloric sufficiency to promote glucose utilization and limiting fat oxidation in 
skeletal musce4. It is important to note other biologic functions that may also potentially affect health 
including endothelial function5 and development of the nervous system2,6.
The roles of adropin in human physiology are not as clear. In women, we recently reported a positive 
association between plasma adropin concentrations and dietary fat consumption7 and increased plasma 
adropin concentrations at 3 and 6 months following Roux-en-Y gastric bypass8. Fish oil supplements 
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added to a high sugar diet increased plasma adropin concentrations in nonhuman primates9. These 
intriguing results suggest a link between diet and circulating adropin levels. However, whether diet affects 
plasma adropin concentrations in humans is unclear.
To address this gap in knowledge, plasma adropin concentrations were measured in samples obtained 
at baseline and after consumption of glucose, fructose or high fructose corn syrup (HFCS) as 25% of 
energy (E) for 2 wk (Study A)10, or glucose or fructose as 25%E for 10 wk (Study B)11,12. These studies 
were designed to determine whether fructose consumption affects cardiovascular and metabolic risk 
factors. As dietary fat alters adropin expression in mice1,2,13,14, we investigated whether dietary fat intake 
would increase plasma adropin concentrations in humans using samples collected after consumption of 
a breakfast meal containing medium- or long-chain triglycerides (TG) (Study C)15.
Results
Biometrics for the participants of Studies A and B whose plasma were used in the current experiments 
are shown in Table  1. Study A subjects consuming glucose, fructose or HFCS gained 0.4 kg (P < 0.05, 
paired t test), 0.1 kg, and 0.8 kg (P < 0.05, paired t test) body weight, respectively (Table 1)10. In Study B, 
fructose and glucose consumption had comparable effects on body weight (Table  1), but had different 
effects on regional body fat distribution11. Glucose consumption increased subcutaneous adipose tissue 
volume, while fructose consumption resulted in a preferential expansion of visceral adipose tissue as 
assessed by computerized tomography.
Plasma adropin concentrations at baseline and after dietary intervention are shown for Study A 
and Study B (Table  2). Baseline adropin concentrations were similar between groups in both stud-
ies. For Study A, there was a trend for significant interaction between sugar and time (F2,75 = 2.830, 
P = 0.069), although the effect of time was not significant (F2,75 = 0.898, P > 0.05). Analysis of the 
change of plasma adropin concentrations (Δ Adropin) indicated that glucose and fructose consumption 
were having opposite effects (Fig. 1A,B), with a trend (F2,75 = 1.683, P = 0.061) for a difference between 
the three groups. Post hoc analysis indicated a tendency (P = 0.057) for a difference, with fructose 
consumption increasing and glucose consumption reducing plasma adropin concentrations (Fig. 1B). 
Plasma adropin concentrations were not significantly affected by HFCS (Fig.  1A,B). While glucose 
appeared to have a more pronounced effect on plasma adropin concentration in males (Fig. 1A), there 
was no significant effect of sex.
A similar differential response to glucose and fructose was observed in Study B. Again, there was a 
strong trend for an interaction between diet and sugar (F1,26 = 3.320, P = 0.08) with no effect of time 
(F1,26 = 1.741, P > 0.05). As before, there was a trend for a difference in Δ Adropin between the glucose 
(reduced) and fructose (increased) groups (F1, 26 = 3.055, P = 0.092) that was not affected of by sex 
(Fig. 1C,D).
As the effects of glucose and fructose consumption on plasma adropin concentrations were similar in 
the two studies, we performed an additional analysis using combined glucose and fructose data with study, 
age, BMI and ethnicity as covariates. The interaction between sugar and time was now highly significant 
Study Sugar Sex N Age (yr)
Weight (kg) 
(pre/post)
BMI (kg/m2) 
(pre/post)
Body fat 
(%) (pre)
BPsys 
(pre)
BPdiast 
(pre)
A (2 wk)
Glucose
M 15 26.5 ± 1.6 78.9 ± 3.3 79.5 ± 3.4
25.6 ± 0.9 
25.8 ± 0.9 23.1 ± 1.6 124 ± 2 75 ± 2
F 13 25.4 ± 1.5 71.6 ± 3.4 72.3 ± 3.6
26.0 ± 1.0 
26.2 ± 1.1 35.6 ± 1.3 112 ± 3 72 ± 2
Fructose
M 15 26.5 ± 1.8 79.1 ± 3.5 79.0 ± 3.5
24.6 ± 0.9 
24.6 ± 0.9 22.3 ± 2.3 122 ± 2 74 ± 2
F 13 27.2 ± 1.6 71.8 ± 3.2 72.0 ± 3.1
26.2 ± 1.0 
26.3 ± 1.0 36.6 ± 1.5 111 ± 2 69 ± 2
HFCS
M 13 23.8 ± 1.8 74.1 ± 3.4 75.2 ± 3.5
23.8 ± 0.9 
24.1 ± 0.9 17.8 ± 1.6 120 ± 2 73 ± 2
F 13 29.7 ± 1.6 69.2 ± 4.3 69.7 ± 4.3
25.5 ± 1.3 
25.7 ± 1.3 33.9 ± 1.7 113 ± 3 72 ± 2
B (10 wk)
Glucose
M 6 55.0 ± 3.5 86.4 ± 3.1 90.3 ± 3.3
28.1 ± 1.1 
28.8 ± 1.2 28.1 ± 3.8 120 ± 2 75 ± 2
F 8 56.0 ± 1.9 83.9 ± 4.6 85.0 ± 4.9
29.4 ± 1.4 
29.8 ± 1.4 42.2 ± 3.1 123 ± 2 79 ± 2
Fructose
M 9 51.8 ± 3.5 88.9 ± 2.9 90.6 ± 2.8
28.5 ± 0.7 
29.0 ± 0.6 26.8 ± 6.1 120 ± 2 76 ± 1
F 8 52.9 ± 2.4 81.8 ± 4.3 82.5 ± 4.3
30.3 ± 1.1 
30.6 ± 1.1 41.2 ± 5.5 120 ± 3 77 ± 3
Table 1.  Biometrics for Study A and B participants (mean, SE).
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(F1,76 = 10.914, P = 0.001), with no significant effect of time (F1,76 = 0.906, P > 0.05) (Fig. 1E,F). The other 
parameters had no impact on the effects of sugar (effect of age, F1,76 = 0.020, P > 0.05; BMI, F1,76= 1.202, 
P> 0.05; ethnicity, F1,76 = 0.054, P > 0.05; sex, F1,76 = 0.047, P > 0.05; and study, F1,76 = 0.072, P > 0.05). 
A univariate analysis comparing Δ Adropin between glucose and fructose with study, sex, age, BMI and 
ethnicity as covariates also indicated a highly significant difference (F1,75 = 9.994, P < 0.005) (Δ Adropin in 
ng/ml for glucose, − 0.26 ± 0.15 ng/ml, 95% CI − 0.55, + 0.04, N = 42; fructose, + 0.32 ± 0.13 ng/ml, 95% 
CI − 0.06, + 0.58, N = 45) (Fig. 1G).
A positive interaction between baseline TG levels and fructose consumption on plasma adro-
pin concentrations. Inspection of Δ Adropin for Study A and B participants consuming glucose or fruc-
tose indicated a responder/non-responder scenario (Fig.  2). With glucose consumption, approximately 
2/3 of the group (27/42) exhibited a decline in plasma adropin (Fig.  2A). With fructose consumption, 
plasma adropin levels increased in ~60% of the subjects (25/45) (Fig. 2B).
A large body of data related to lipid and glucose metabolism had been collected from all participants 
during the original experiments10,11. We therefore examined whether responders and nonresponders 
are distinguished by differences in risk factors for cardiovascular disease and type 2 diabetes. This ini-
tially involved an unbiased screen for associations between the plasma adropin concentrations (baseline, 
post-intervention and Δ Adropin) and previously collected plasma lipid and glucose metabolic parameters. 
To differentiate between responders and non-responders, we separated data pooled from Study A and 
B into quartiles ranked by Δ Adropin. To determine whether the differences in Δ Adropin in each quartile 
correlated with plasma lipid and lipoprotein risk factors, we performed an initial screen of the risk fac-
tors comparing baseline values in the 1st and 4th quartiles using a Student’s t-test. Factors that showed 
significant differences (P < 0.05) in Δ Adropin between the 1st and 4th quartile were then analyzed further 
using ANOVA.
This strategy did not identify distinguishing characteristics in the glucose group. However, the results 
of this analysis suggest differences in plasma TG between the 1st and 4th quartiles in participants consum-
ing fructose. Further analysis of fasting TG (TGfst) (Fig. 3A), the total area under the curve (TGtotAUC) 
(Fig.  3B), and the incremental area under the curve (TGiAUC) (Fig.  3C) indicated a higher circulating 
TG profile in the 4th quartile group compared with the other 3 quartiles. This was significant for TGiAUC, 
which was markedly (> 2-fold) higher in individuals in the 4th relative to all other quartiles (P < 0.05). 
Distribution by age and sex was similar in the 4 groups (mean ± SE of the age for the 1st to 4th quartiles, 
38.2 ± 5.1 yr, 32.7 ± 3.5 yr, 38.4 ± 4.2 yr and 37.8 ± 4.7 y; number of males and females in the1st to 4th 
quartiles, 7 male/4 female, 7/4, 3/8 and 6/5). There were also significant correlations between Δ Adropin 
and baseline values for TGFst (r = 0.391, P < 0.01), TGiAUC (r = 0.479, P = < 0.005) and TGAUC(r = 0.473, 
P < 0.005) (Fig. 3D–F).
Of note, the most pronounced fold-increase (3.8 fold) of adropin with fructose consumption was 
observed in a female in Study B (age 53 yr, BMI 34.4 kg/m2) who also had the lowest plasma adropin 
concentrations measured in these studies (0.6 ng/ml) and high risk factors for cardiovascular disease. 
The individual had the highest TG levels at baseline (TGfst 342 mg/dl, + 2.9 SD from the mean for all 
Study Sex Sugar (N) Baseline 2 wk
A (2 wk)
Males Glucose (15) 3.95 ± 0.44 3.50 ± 0.37
Fructose (15) 4.13 ± 0.49 4.31 ± 0.54
HFCS (13) 3.74 ± 0.56 3.64 ± 0.41
Females Glucose (13) 3.03 ± 0.30 2.92 ± 0.19
Fructose (13) 3.81 ± 0.55 4.02 ± 0.66
HFCS (13) 3.12 ± 0.31 3.15 ± 0.27
All Glucose (28) 3.52 ± 0.28 3.23 ± 0.22
Fructose (28) 3.98 ± 0.36 4.18 ± 0.42
HFCS (26) 3.43 ± 0.32 3.39 ± 0.24
B (10 wk)
Sex Sugar (N) Baseline 10 wk
Males Glucose (6) 3.98 ± 1.21 3.75 ± 1.20
Fructose (9) 3.60 ± 0.81 4.09 ± 1.00
Females Glucose (8) 3.35 ± 0.44 3.10 ± 0.39
Fructose (8) 2.46 ± 0.42 2.90 ± 0.48
All Glucose (14) 3.62 ± 0.56 3.38 ± 0.54
Fructose (17) 3.06 ± 0.48 3.53 ± 0.58
Table 2.  Plasma adropin concentrations at baseline and after sugar consumption.
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Figure 1. Effects of sugar consumption on plasma adropin concentrations. (A) The change (Δ ) in plasma 
adropin concentrations is shown for males (M, N = 43) and females (F,N = 39) who consumed glucose 
(N = 28; 15M, 13F), fructose (N = 28; 15M, 13F) or HFCS (N = 26, 13M, 13F) for 2 wk (Study A). (B) There 
was no significant effect of sex; data grouped by sugar type only are also shown. (C) Change (Δ ) in plasma 
adropin concentrations is shown for males (M, N = 15) and females (F, N = 16) who consumed glucose 
(N = 14; 6 M, 8 F) or fructose (N = 16; 9M, 8F) for 10 wk (Study B). (D) There was no significant effect of 
sex; data from Study B grouped are also shown grouped by sugar type. (E–F) Data pooled from Study A 
and B for the glucose and fructose groups. (E) Males (M, N = 45) and females (F, N = 42) exhibited similar 
responses to glucose (N = 42) or fructose (45) consumption; *P < 0.01. (F) Plasma adropin levels at baseline 
were similar for the glucose and fructose groups, but then diverged with the consumption of glucose 
or fructose as 25% of daily energy requirements. (G) The difference in the effect of glucose or fructose 
consumption on plasma adropin levels was highly significant. *P < 0.01.
Figure 2. Individuals vary in their response to glucose or fructose consumption. (A) Change in plasma 
adropin concentrations (Δ ng/ml) with glucose consumption in individuals. (B) Change in plasma adropin 
concentrations with fructose consumption in individuals. The data shown in panels (A,B) are combined 
from Study (A) and Study (B).
www.nature.com/scientificreports/
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participants in Study B; TGiAUC 2411 mg/dl/23h, + 2.8 SD; TGtotAUC 10619 md/dl/23 h, + 2.9 SD). This 
participant also had very high levels of fasting TG- and cholesterol-rich remnant lipoproteins (RLPTGfst 
153.0 mg/dl, + 4.4 SD from the mean of 27.7 mg/dl in Study B; RLPCfst 26.6 mg/dl, + 4.3 SD from the 
mean of 7.4 mg/dl in Study B).
An acute effect of fat consumption on plasma adropin concentrations. In the next experiment 
we examined whether dietary lipid intake would rapidly affect plasma adropin concentrations. Physical 
characteristics of the Study C participants have been reported previously15. Participants were provided 
a breakfast supplemented with 20 g of test oils comprised of either medium-chain or long-chain TG 
(MCT, LCT), in a 2-arm, randomized, single-blind, cross-over design as previously described15. The 
initial analysis of plasma adropin concentrations following consumption of MCT or LCT suggested no 
effect (Fig.  4A). However, further analysis of the increase in plasma adropin concentrations following 
the meal suggested a potential responder/nonresponder situation following MCT and LCT consumption, 
with an inverse association between the AUC and baseline plasma adropin concentrations (Fig. 4B). The 
postprandial area under the curve (AUC) for adropin also tended to be higher following MCT compared 
with LCT (AUC in ng/ml/2 h for MCT, 0.6 ± 0.5, for LCT, − 0.5 ± 0.3; F1,9 = 4.081, P = 0.074). The potential 
responder/nonresponder situation was further analyzed by grouping the highest and lowest “responders” 
(AUC in ng/ml per 2 h for high responders to MCT, 2.9 ± 0.7, low responders, − 1.0 ± 0.4, P < 0.01; for 
higher responders to LCT, 0.6 ± 0.2; low responders, − 1.4 ± 0.2, P < 0.01). Interestingly, participants exhib-
iting the largest increase in response to MCT (“responders) also appeared to have lower plasma adropin 
concentrations at baseline (Fig. 4C). For LCT, when divided into low and high responders a similar differ-
ence in the AUC was evident (adropin concentrations at T-15 for high responders, 1.9 ± 0.2 ng/ml; for low 
responders, 2.8 ± 0.1 ng/ml, P < 0.05). However, the distinction between responders and nonresponders 
was less clear for LCT, with nonresponders showing a dip following breakfast (Fig. 4D). The differences 
in the response to MCT and LCT, and the ambiguity of the responder/nonresponder situation following 
Figure 3. Association between the increase in plasma adropin levels with fructose consumption and 
fasting TG (A,D), total area under the curve for TG over 23 h (B,E) and integrative area under the curve 
for TG over 23 h (C,F). The TG shown in (A–C) are averages based on quartile for Δ adropin adjusted for age, 
sex, BMI and % body fat. The quartiles are for Δ adropin ranked from 1st (lowest) to 4th (highest). *P < 0.05 
vs. 1st and 3rd quartile. Scatterplots shown in (D–F) have baseline TG data (fasting, total or integrative area 
under the curve) in the y-axis, and Δ adropin in the x-axis.
www.nature.com/scientificreports/
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LCT consumption, may be due to plasma samples from the two strongest responders to MCT not being 
available for the LCT arm of the study.
Discussion
To our knowledge there has been only one report suggesting that plasma levels of adropin in humans 
are responsive to changes of energy balance, increasing after Roux-en Y gastric bypass8. Our data are 
therefore significant for being the first to suggest that diet coupled with systemic TG metabolism has 
an important influence in regulating plasma adropin concentrations in humans. We found that glucose 
consumption lowers while fructose increases plasma adropin concentrations. The differential effect of 
fructose and glucose was corroborated by an intermediate essentially zero effect, in Study A subjects 
consuming HFCS which is composed of 55% fructose and 45% glucose.
While the averaged response appears small (5–10%), there was considerable variability between indi-
viduals suggesting interactions between sugar and other variables. In the fructose group, the partic-
ipants exhibiting the largest increases of plasma adropin had higher baseline circulating TG profiles. 
This outcome suggests an association between elevated TG levels and the regulation of plasma adropin 
concentrations in humans.
The consistency in the outcomes observed in the two different 2 wk and 10 wk treatment paradigms 
is a strength of this study. However, data interpretation is complicated by the lack of specific information 
regarding the molecular mechanisms by which circulating adropin levels are regulated. The observed 
changes are presumably indirect downstream consequences of changes in lipid and glucose metabolism 
associated with sugar consumption. Glucose passes through the liver and is readily oxidized as needed or 
converted to glycogen. In contrast, fructose is retained by the liver and is more readily converted to fatty 
acids and exported as very-low density lipoproteins. Consumption of diets with high fructose content 
has been suggested to promote risk factors for cardiovascular and metabolic risk disease. Indeed, in the 
studies from which these plasma samples were obtained, fructose consumption was associated with the 
development of dyslipidemia10,11 and insulin resistance11.
It is of interest to note the parallels between the effects of adropin and fructose consumption on fuel 
selection. In mice, adropin limits fat oxidation while enhancing glucose oxidation in lean and diet-induced 
obese mice3,4. In the 10wk study, fructose consumption lowered insulin sensitivity, increased de novo 
Figure 4. Effects of MCT or LCT consumption on plasma adropin concentrations suggests a responder/
nonresponder situation. (A) Averages in the absolute values and delta (Δ , values at the various time points 
minus baseline) following MCT or LCT consumption. (B) Inverse association between the area under the 
curve (AUC) for the change in plasma adropin concentrations and baseline values taken 15 minutes before 
consumption of meals containing MCT or LCT. (C) Individuals who are “responders” exhibit a marked 
increase in plasma adropin concentrations after consumption of MCT when compared to “low responders”. 
“High responders” are characterized by having low plasma adropin concentrations at baseline, with MCT 
consumption increasing plasma adropin levels to that observed in “low responders”. *P < 0.05. (D) The 
distinction between responders and nonresponders following LCT consumption is less clear. While the Δ 
in plasma adropin was higher in responders, this was due to nonresponders showing a marked decline in 
adropin following consumption of the meal.
www.nature.com/scientificreports/
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lipogenesis, reduced postprandial fat oxidation, and enhanced glucose oxidation, and, even though 
weight gain was similar for both groups, only fructose consumption increased intra-abdominal obe-
sity11,12. If adropin has similar functions in humans, then the increase in plasma adropin concentrations 
with fructose consumption is consistent with the outcomes observed in fuel selection (i.e., reduced net 
postprandial fat oxidation, enhanced net postprandial carbohydrate oxidation)11,12. The positive asso-
ciation between high TG at baseline and the impact of fructose consumption on plasma adropin con-
centrations is also suggestive (Fig. 4). If adropin limits fat oxidation in humans as it does in mice, then 
inhibition of fat oxidation might be one of several factors contributing to elevated TG levels following 
fructose consumption.
Previous findings on the metabolic response of humans to MCT are, however, not consistent with this 
hypothesis. While MCT appear to have a stimulatory effect on plasma adropin concentrations, they are 
preferentially oxidized and cause a net increase in energy expenditure and fat oxidation16,17. Moreover, 
although plasma TG increased after consumption of MCT and LCT, the response was lower following 
MCT15. The association between fructose consumption, system TG metabolism and plasma adropin 
concentrations may therefore involve other indirect time-dependent mechanisms.
Whether fructose consumption would similarly affect plasma adropin concentrations in rodents as 
observed in humans has not been determined. It is worth noting that the provision of fructose to mice 
has also been observed to increase adiposity by enhancing lipogenesis and reducing energy expendi-
ture18,19. An increase of plasma adropin would serve to facilitate the expansion of the fat reserves by 
reducing fatty acid oxidation while promoting the oxidation of carbohydrates. Future studies investigat-
ing whether fructose consumption affects adropin expression in mice, and whether adropin regulates fuel 
selection in humans, are required.
One caveat to this model is that over expression of adropin or administration of adropin peptide to 
mice does not result in obesity2. Indeed, transgenic mice over expressing adropin under the control of 
the human β -actin promoter exhibit delayed DIO, while treatment of DIO male B6 mice with synthetic 
adropin is associated with mild weight loss. In both cases, a shift away from fat oxidation towards glucose 
oxidation has been observed3,4. One possible explanation for this discrepancy is that the mouse models 
represent a non-physiological condition. In the studies with administration of synthetic adropin peptide, 
the doses used are pharmacological, likely resulting in spikes in plasma adropin concentrations well 
above what is normally observed in the fed condition. For the transgenic mice, the use of the β -actin 
promoter results in high levels of expression in tissues where the endogenous Enho gene is either not 
active or expressed at low levels. A mild increase in plasma adropin observed in physiological conditions 
may therefore be sufficient to alter fuel selection without producing changes in metabolism that prevent 
weight gain.
Finally, another perhaps simpler interpretation of this data is that there is a link between hypertriglyc-
eridemia and plasma adropin levels. This might involve a homeostatic interaction between adropin and 
TG metabolism. In mice, adropin appears to be stimulated by dietary fat content. Adropin also has an 
inhibitory effect on the expression of genes involved in lipogenesis, although whether this effect is direct 
or secondary to other metabolic changes has not been determined2. The association between baseline 
TG levels and the increase in plasma adropin concentrations might therefore indicate an attempt to 
maintain homeostasis.
The second part of this study examined plasma adropin concentrations following consumption of 
a high fat meal. The samples used for this experiment came from a study comparing the response 
of adult men to a breakfast meal supplemented with 20 g of MCT or LCT15. The original goal of 
the study was to compare the satiating effects of MCT with LCT, including an analysis of gut hormone 
responses.
The results of our analysis suggest a complex situation with regard to the response of plasma adropin 
to dietary fats in humans. The impact of dietary fat on plasma adropin concentrations appears to be 
dependent on baseline levels, with an inverse relationship. Strong linear associations between the post-
prandial AUC and baseline fasting plasma adropin concentrations were evident. While this was evident 
for both LCT and MCT, the latter appear to have elicited a more potent effect in those individuals who 
are “responders”. Indeed, one interpretation of our data is that individuals with plasma adropin concen-
trations at the low end of the spectrum will experience a rapid increase following ingestion of meals 
rich in fats.
The main outcomes of this report should be considered preliminary as none of the studies from 
which samples were obtained were specifically designed to investigate the regulation of circulating adro-
pin. However, these results are important in suggesting that further studies investigating the impact of 
macronutrient consumption on plasma adropin concentrations are needed.
These results suggest an association between dietary and systemic lipid/triglyceride metabolism in 
the regulation of plasma adropin concentrations. Lipids originating either from the diet or from endog-
enous production appear to positively affect plasma adropin concentrations in humans. Further studies 
designed to specifically investigate the mechanisms linking lipid metabolism to plasma adropin concen-
trations are warranted.
www.nature.com/scientificreports/
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Methods
The protocols used for original studies were reviewed and approved by the Institutional Review 
Boards at UC Davis10,11 and St. Luke’s/Roosevelt Hospital15. The studies were subsequently performed 
in accordance following the guidelines provided by the IRB’s at UC Davis and St. Luke’s/Roosevelt 
Hospital. All of the participants provided written informed consent for the use of plasma collected in 
the experiments. Plasma adropin concentrations at baseline from Study A and Study B were reported 
previously8.
Study A (UC Davis CCRC, 2 wk dietary intervention examining the effect of glucose, fructose or 
HFCS on plasma adropin concentrations. Clinical Trials.Gov Identifier NCT01103921). Plasma 
for this experiment was from 82 participants (43 males, 39 females) of mixed ethnicity (44 Caucasian, 9 
Hispanic, 13 Asian, 11 African American, 3 Pacific Islander and 2 of mixed heritage). Biometric data are 
shown in Table 1. Recruiting, exclusion criteria and study design are published10. The study consisted of 
three phases. In phase one, study participants resided at the CCRC for a 3.5-d inpatient baseline period. 
During the second and third day, study participants were provided energy-balanced meals consisting of 
conventional foods. The diet during this period contained 55%E as complex carbohydrate, 30% fat and 
15% protein served as 3 meals, with 25% of the energy provided as breakfast at 0900 h, 35% as lunch 
(1300 h) and 40% as dinner (1800 h). In phase two, a 12-d outpatient period, participants were provided 
with sugar-sweetened beverages providing 25%E split between three meals (breakfast, lunch and dinner). 
Participants were asked to consume one beverage per meal, to consume their normal diet, and to not to 
consume other sweetened beverages (including fruit juice). Phase three involved another 3.5-d inpatient 
period at the CCRC with participant provided energy balanced meals derived from conventional foods 
and sugar-sweetened beverages. Pooled samples collected at 0800, 0830 and 0900 h after an overnight 
fast on the third day of the baseline period and third phases were used to measure plasma adropin at 
baseline and after 2 wk of dietary intervention.
Study B (UC Davis CCRC, 10 wk dietary intervention examining the effect of glucose or fruc-
tose on plasma adropin concentrations. Clinical Trials.Gov Identifier NCT01165853). Plasma 
used for this study was obtained from 32 participants (16 males, 16 females; 24 Caucasian, 5 Hispanic, 3 
African American) consuming 25%E from fructose or glucose for 10 wk11. Biometrics are presented in 
table 1. This study also consisted of three phases. An inpatient baseline period lasted for 2 wk where par-
ticipants consumed an energy balanced diet. The second phase involved an 8 wk outpatient period, with 
participants provided fructose- or glucose-sweetened beverages providing 25%E. The final phase was a 2 
wk inpatient period involving continued consumption of the fructose- or glucose-sweetened beverages. 
The meals provided during the inpatient periods were comprised of 55%E as carbohydrate, 30%E as fat 
and 15%E as protein. Pooled samples collected at 0800, 0830 and 0900 h after an overnight fast on the 
final day of the baseline period and third phases were used to measure plasma adropin.
Study C (NYONRC, effect of medium or long chain triglyceride consumption on plasma adro-
pin concentrations. Clinical Trials.Gov Identifier NCT01952977). Physical characteristics have 
been reported15. The study was comprised of 5 Caucasian, 8 African American, 2 Hispanic and 2 men 
of mixed heritage, aged 39.4 ± 1.8y who were overweight (mean body weight, 88.9 ± 2.3 kg; mean BMI, 
28.2 ± 0.3 kg/m2). In brief, this study was performed in two parts (C1, C2). Ten men participated in 
Study C1; the protocol was then revised and another 7 men enrolled into Study C2. Each study involved 
a 2-arm, randomized, single-blind, cross-over design. Each arm consisted of a test day spaced 3 to 14 d 
apart that differed in the type of oil incorporated into the meal: MCT oil (Neobee 1053, Stepan Company, 
Northfield, IL) or corn oil (LCT, Mazola, ACH Food Companies, Cordova, TN). The nutrient composi-
tion of the breakfast meals was different (C1: muffin with test oil added and orange juice, total energy 
2671 kJ, 105 g carbohydrate, 9.6 g protein, 20 g of fat, 20 g of test oil; C2: boost shake with test oil, total 
energy 2510 kJ, 71.6 g carbohydrate, 17.5 g protein, 27 g of fat, 20 g of test oil). Both diets provided the 
same amount of test oil. For 2 d prior to the test, participants were requested not to consume alcohol or 
participate in structured exercise. They were asked to record their food intake at dinner the night before 
the test day and consume the same meal the night before the follow-up test day. The participants fasted 
for at least 12 h during the night before the test day.
Plasma adropin measurements. Adropin concentrations were measured using EDTA-plasma not 
previously been thawed in duplicate by EIA (Peninsula Laboratories, Bachem, San Carlos, CA)8. The 
intra-assay coefficient of variation (CV) is < 10%, while the inter-assay variability fluctuates between 20 
to 30%.
Statistical analysis. Data analysis used SPSS Statistics 22. Univariate analysis with repeated measures 
(within-subjects factors: time at pre- and post-intervention) was used to determine the impact of die-
tary intervention, with sugar type as between-subjects factors in the analysis. For comparisons between 
sugar groups involving single measurements (for example, the change in plasma adropin concentrations 
calculated by subtracting baseline from the post-intervention value), ANOVA were used followed by 
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Bonferroni corrected multiple comparisons. For analyzing the response to MCT and LCT, which was a 
randomized cross-over design, a pair t-test was used for the analysis of the AUC.
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